|Reference||Data Source||n||Time Period||Mortality Rate||Higher Mortality Risk||Lower Mortality Risk|
|Brophy et al. (4)||Registry||153||Late 1980s to early 1990s||61% in 47 months|
|EFFECT, Lee et al. (7)||Registry||4,031||1997–2001||Increased SBP|
|Aronson et al. (3)||Clinical trial||541||1996–1999||33%, mean follow-up 343 (± 185) days||Increased SBP|
|OPTIME-CHF, Felker et al. (2)||Clinical trial||949||1997–1999||9.6% 60-day mortality|
|ADHERE, Adams et al. (15)||Registry||2001–2003||SBP ≥115 mm Hg|
|OPTIMIZE-HF||Registry||48,612||2003–2004||3.8% in-hospital mortality|
ADHERE = Acute Decompensated Heart Failure National Registry; CVA/TIA = cerebrovascular accidents/transient ischemic attacks; EFFECT = Enhanced Feedback for Effective Cardiac Treatment; NYHA = New York Heart Association; OPTIME-CHF = Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure; other abbreviations as in Tables 1 and 3.